IIPR's Second Landlord: Life Science Now Pays a Quarter of the Rent
Record cannabis re-leasing and a $545 million IQHQ bet collide with a quietly softened rescheduling story and a dividend covered by recoveries, not run-rate
IIPR · Earnings Call · 2026-11-03
The pivot stops being a hedge
For five quarters, Innovative Industrial Properties has described life science as diversification. This quarter it became an income statement line. Executive Chairman Alan Gold put a number on it: “we have now committed approximately $545 million to life science. Upon full funding, our life science investments are projected to account for ~26% of our total annualized income” — Alan D. Gold, Executive Chairman · 2026-11-03. That is not a toe in the water. That is a second business. The vehicle is Alewife Park — a 27-acre Cambridge, Massachusetts campus with three buildings totaling 392,000 square feet, 78% leased to Lila Sciences (an AI-enabled scientific discovery company), plus two pad-ready sites with up to 364,000 square feet of development. IIPR funded $111 million at closing on its $245 million mezzanine loan commitment, with $134 million more expected through the fourth quarter of 2027, and an option to pick up another $155 million from a syndicate partner on the same terms. The average interest rate is roughly 15.8%. Strip the label off and this is a 15.8% secured credit position sitting behind IQHQ's roughly $4 billion of raised equity — a very high accretive investment only if the underlying campus leases up. The company's own evidence is directional and third-party: JLL data cited on the call shows combined demand in Boston, San Diego, the Bay Area and Raleigh-Durham up 44% year over year to nearly 8 million square feet in Q1 2026. The listed tape is already paying for that recovery elsewhere — life science tools and clinical-stage biotech names are among the strongest 90-day movers in the global theme set, with early-stage oncology cohorts up 30-80%. IIPR is lending into a funding recovery the equity market has already begun to underwrite.Record leasing — and the arithmetic that comes with it
On the cannabis side the operating story genuinely improved. The company executed new leases on 604,000 square feet across six properties in Q3, added 270,000 square feet in Pennsylvania after quarter-end, and reached roughly 1.3 million square feet across 12 properties year to date — about 15% of the portfolio. Another 446,000 square feet sits in signed-but-not-inked agreements (72,000 square feet across three Colorado properties; 374,000 square feet across three former 4Front assets). Two things keep this from being a clean inflection. First, the re-tenanting economics: management again stressed costs well below $10 a foot all-in — a claim echoed in the February and May calls at $15 and below, and $5-to-$10. Efficient, but it also means the new rents on backfilled space are not comparable to legacy rents. Second, the remaining hole is concentrated: “currently is a little over 800 thousand square feet... two-thirds of that is our 2 parallel assets in Florida” — Ben Regin, Chief Investment Officer · 2026-11-03. Florida is the right market to be stuck in — 22 new vertically integrated licenses, record July sales, roughly 20% year-over-year growth — but it is still one tenant exit sitting in one state.The dividend is covered by a recovery, not a run-rate
AFFO of $54.8 million, or $1.96 per share, was up 7% sequentially and pushed the payout ratio to 97% against the $1.90 quarterly dividend. Buried in that number: $0.15 per share of past-due rent recoveries, primarily Battle Green, plus recoveries tied to PharmaCann and Parallel that management itself labeled non-recurring. When Bill Kirk asked directly whether quarterly AFFO stays above the payout, the CFO answered with history rather than a number: “In terms of the go forward, obviously, do not give guidance. I think we have done a great job historically of recovering these past due rent payments that are owed to us” — David J. Smith, Chief Financial Officer · 2026-11-03. The cushion behind those recoveries is also shrinking. Four of the five defaulted tenants have fully exhausted their security deposit balances, with only The Cannabis Company still holding any. And the underlying engine is still contracting: Funds From Operations came in at $50 million in the June quarter, down 14% year over year and 18% below the 2024 peak. Per-share AFFO optics and the FFO trajectory are telling two different stories.What management stopped saying
This is the quietest change on the call. In May, rescheduling was a live, imminent catalyst. Paul Smithers then: “we are thrilled that it's on this expedited time line... I think it's pretty darn clear about the decision to bifurcate” — Paul Smithers, President and Chief Executive Officer · 2026-05-05, with 100% of the portfolio's operators holding medical licenses already benefiting from Schedule III treatment. On this call it became a docket item:The keyword record corroborates the de-escalation. Schedule III and administrative hearing were among the single largest decliners in the company's own keyword momentum last quarter, and the earlier vocabulary — 280E relief, interstate commerce, medical operators, the Attorney General — has dropped out of the top-30 entirely. Nothing was wrong with the answer; the subject simply stopped being pitched. When a bull case's primary catalyst migrates from "expedited" to "uncertain," that migration is the news.While the proceedings remain subject to further administrative review, and the timing and outcome of any final decision remains uncertain, we believe federal reform has the potential to provide meaningful benefits to operators
The cost of the pivot, and the tape that isn't paying for it
The balance sheet headline is genuinely strong — “we ended the quarter with net debt to adjusted EBITDA of 2.1x, 1 of the lowest in the REIT industry” — David J. Smith, Chief Financial Officer · 2026-11-03, net debt at 19% of gross assets, and $142 million of liquidity before the $54 million 9.25% Series B preferred raise. But the direction of travel is less comfortable. Interest expense reached $8 million, up 88% year over year. Interest coverage has fallen to 5.0x from a 14.8x peak, and liabilities to assets rose 9.9 percentage points year over year to 28.3%. Structurally, IIPR is now funding a 15.8% mezzanine loan with 9.25% perpetual preferred and a revolver that is only $87.5 million and was extended 90 days to January 2027. The spread works; the concentration does not. One private counterparty, IQHQ — the company Alan Gold co-founded — now represents roughly a quarter of annualized income, and the Board has signaled it would keep going if opportunities appear. Compare that to November 2025:Asked in May whether the eventual mix might be 50-50 or 25-75, Gold deflected: “I think that that is a very difficult question to answer” — Alan Gold, Executive Chairman · 2026-05-05. The answer arrived anyway, on this call, in a percentage. The market has not rewarded it yet. IIPR shares are down about 11% over the last 90 trading days and sit 18% below the July 16 peak of $64.67, still 81% under the 2021 high. A record leasing quarter and a fresh 26%-of-income credit business landed into that fade. The fourth quarter will tell us whether Alewife's first full period of interest income plus Florida re-tenanting can move AFFO above the dividend on its own merits — or whether coverage stays a function of collections from tenants who already stopped paying once.I think our primary focus will remain in the cannabis industry